Monoclonal antibodies binding data for SARS-CoV-2 proteins

Nawneet Mishra; Joan Teyra; RuthMabel Boytz; Shane Miersch; Trudy N Merritt; Lia Cardarelli; Maryna Gorelik; Filip Mihalic; Per Jemth; Robert A Davey; Sachdev S Sidhu; Daisy W Leung; Gaya K Amarasinghe

doi:10.1016/j.dib.2022.108415

Monoclonal antibodies binding data for SARS-CoV-2 proteins

Data Brief. 2022 Aug:43:108415. doi: 10.1016/j.dib.2022.108415. Epub 2022 Jun 24.

Authors

Affiliations

¹ Department of Pathology and Immunology, Washington University School of Medicine in St Louis, St Louis, MO 63110, U.S.A.
² The Donnelly Centre, University of Toronto, Toronto, Canada.
³ Department of Microbiology, Boston University School of Medicine, St Louis, MO 63110, U.S.A.
⁴ Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, U.S.A.
⁵ Department of Medical Biochemistry and Microbiology, Uppsala University, B.M.C. Box 582, Husargatan 3, 751 23 Uppsala Sweden.

Abstract

SARS-CoV-2 pandemic opens up the curiosity of understanding the coronavirus. This demand for the development of the regent, which can be used for academic and therapeutic applications. The present data provide the biochemical characterization of synthetically developed monoclonal antibodies for the SARS-CoV-2 proteins. The antibodies from phage-displayed antibody libraries were selected with the SARS-CoV-2 proteins immobilized in microwell plates. The clones which bind to the antigen in Fab-phage ELISA were selected, and a two-point competitive phage ELISA was performed. Antibodies binding kinetic of IgGs for SARS-CoV2 proteins further carried with B.L.I. Systematic analysis of binding with different control proteins and purified SARS-CoV-2 ensured the robustness of the antibodies.

Keywords: B.L.I.; ELISA; SARS-CoV-2.

Abstract

Grants and funding